© RIA Novosti / Pavel Lisitsyn
The NTI Venture Fund will invest 180 million rubles in the project of a medical diagnostics platform based on artificial intelligence (AI) technology “Celsus”, according to the Russian Venture Company (RVC).
It is noted that the platform is designed to help doctors make decisions in the field of radiology and Oncology. The system recognizes the presence of benign or malignant changes in medical images, indicates their location, and then interprets the results according to international standards. The accuracy of interpretation of the results of the analysis of mammography studies is more than 95%, and fluorography studies is 93%.Currently, finished products for mammography and fluorography have been created, and solutions in the field of morphology and computed tomography, including COVID-19 diagnostics, are at the final stage of development, according to the release.
The National Technology Initiative (NTI) Venture Fund was launched by 123 in 2018 with the participation of 123 Infrafund. It is managed by the private investment company Kama Flow and invests in Russian deep tech projects at an early stage. Artificial intelligence, big data analysis and storage technologies, microelectronics, new materials and advanced manufacturing technologies are among the priority fields. The volume of the Fund is 3.5 billion rubles.